Compare WLY & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLY | TMDX |
|---|---|---|
| Founded | 1807 | 1998 |
| Country | United States | United States |
| Employees | 5200 | N/A |
| Industry | Books | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | N/A | 2019 |
| Metric | WLY | TMDX |
|---|---|---|
| Price | $47.51 | $66.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $148.22 |
| AVG Volume (30 Days) | 488.3K | ★ 1.0M |
| Earning Date | 06-16-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $1.04 | $24.25 |
| Revenue Next Year | $2.36 | $18.75 |
| P/E Ratio | ★ $15.84 | $388.75 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $28.38 | $60.11 |
| 52 Week High | $48.19 | $156.00 |
| Indicator | WLY | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 39.81 |
| Support Level | $39.68 | $64.90 |
| Resistance Level | $48.19 | $71.14 |
| Average True Range (ATR) | 2.01 | 4.26 |
| MACD | 0.07 | 0.65 |
| Stochastic Oscillator | 88.93 | 7.70 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.